Topic: Blood-brain barrier
The week’s biotech developments included a brain-penetrating compound from scorpion venom and a pact to develop virus-based cancer drugs.
Denali will acquire the rights to bispecific antibodies targeting the blood-brain barrier that were developed under its collaboration with F-star.
With the new financing, Kallyope plans to move its pipeline programs toward the clinic and hire another 16 people.
Oncolytic viruses used in tandem with other treatments could be key for difficult-to-treat breast and brain cancers.
Lundbeck has struck a deal with Ossianix to use shark-derived antibodies to hustle drugs across the blood-brain barrier.